Nautilus Biotechnology (NAUT) to Announce Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT) is expected to be announcing its Q2 2026 results before the market opens on Tuesday, July 28th. Analysts expect the company to announce earnings of ($0.1350) per share and revenue of $0.25 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Tuesday, July 28, 2026 at 8:30 AM ET.

Nautilus Biotechnology (NASDAQ:NAUT) last released its quarterly earnings data on Tuesday, April 28th. The company reported ($0.12) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.02.

Nautilus Biotechnology Price Performance

Shares of NASDAQ NAUT opened at $1.69 on Friday. The stock has a market capitalization of $214.77 million, a P/E ratio of -3.67 and a beta of 0.80. The company has a 50-day moving average price of $2.14 and a 200-day moving average price of $2.45. Nautilus Biotechnology has a 1 year low of $0.62 and a 1 year high of $4.31.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nautilus Biotechnology in a research report on Friday, July 17th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $4.00.

Insider Transactions at Nautilus Biotechnology

In related news, major shareholder Ah Equity Partners Bio Ii, L.L sold 5,000,000 shares of the company’s stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $2.35, for a total transaction of $11,750,000.00. Following the completion of the sale, the insider owned 971,885 shares in the company, valued at approximately $2,283,929.75. This represents a 83.73% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 41.10% of the company’s stock.

Hedge Funds Weigh In On Nautilus Biotechnology

A number of hedge funds have recently bought and sold shares of NAUT. Bank of America Corp DE grew its stake in shares of Nautilus Biotechnology by 37.1% in the 4th quarter. Bank of America Corp DE now owns 49,419 shares of the company’s stock worth $83,000 after acquiring an additional 13,363 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in shares of Nautilus Biotechnology during the first quarter valued at about $194,000. Acadian Asset Management LLC boosted its holdings in Nautilus Biotechnology by 468.3% during the first quarter. Acadian Asset Management LLC now owns 61,735 shares of the company’s stock worth $51,000 after purchasing an additional 50,871 shares during the last quarter. XTX Topco Ltd boosted its holdings in Nautilus Biotechnology by 86.2% during the second quarter. XTX Topco Ltd now owns 66,194 shares of the company’s stock worth $48,000 after purchasing an additional 30,641 shares during the last quarter. Finally, Qube Research & Technologies Ltd bought a new stake in Nautilus Biotechnology in the 2nd quarter worth about $45,000. 50.71% of the stock is owned by hedge funds and other institutional investors.

About Nautilus Biotechnology

Nautilus Biotechnology is a life sciences company developing a next-generation proteomics platform that aims to provide high-resolution, single-molecule protein analysis. Its core technology combines proprietary microfluidics, advanced optics and custom reagents to capture and identify thousands of proteins simultaneously, offering researchers detailed insights into cellular processes and disease biology. The company’s platform is designed to improve sensitivity, reproducibility and throughput compared with traditional mass spectrometry approaches.

Founded in 2016 and headquartered in Seattle, Washington, Nautilus Biotechnology serves pharmaceutical and biotechnology companies, academic institutions and research organizations seeking to accelerate drug discovery and biomarker research.